• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease.

作者信息

Feelders Richard A, de Bruin Christiaan, Pereira Alberto M, Romijn Johannes A, Netea-Maier Romana T, Hermus Ad R, Zelissen Pierre M, van Heerebeek Ramona, de Jong Frank H, van der Lely Aart-Jan, de Herder Wouter W, Hofland Leo J, Lamberts Steven W

出版信息

N Engl J Med. 2010 May 13;362(19):1846-8. doi: 10.1056/NEJMc1000094.

DOI:10.1056/NEJMc1000094
PMID:20463350
Abstract
摘要

相似文献

1
Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease.帕西瑞肽单药治疗或联合卡麦角林及酮康唑治疗库欣病
N Engl J Med. 2010 May 13;362(19):1846-8. doi: 10.1056/NEJMc1000094.
2
The hypercoagulable state in Cushing's disease is associated with increased levels of procoagulant factors and impaired fibrinolysis, but is not reversible after short-term biochemical remission induced by medical therapy.库欣病中的高凝状态与促凝因子水平升高和纤维蛋白溶解受损有关，但在药物治疗诱导的短期生化缓解后并不逆转。
J Clin Endocrinol Metab. 2012 Apr;97(4):1303-10. doi: 10.1210/jc.2011-2753. Epub 2012 Jan 25.
3
Update in the medical therapy of Cushing's disease.库欣病的医学治疗进展。
Curr Opin Endocrinol Diabetes Obes. 2013 Aug;20(4):330-4. doi: 10.1097/MED.0b013e3283631809.
4
Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing's disease.卡麦角林单药治疗和联合酮康唑治疗库欣病的疗效。
Pituitary. 2010 Jun;13(2):123-9. doi: 10.1007/s11102-009-0209-8.
5
Preoperative normalization of cortisol levels in Cushing's disease after medical treatment: consequences for somatostatin and dopamine receptor subtype expression and in vitro response to somatostatin analogs and dopamine agonists.库欣病患者经药物治疗后皮质醇水平术前正常化：对生长抑素和多巴胺受体亚型表达的影响以及对生长抑素类似物和多巴胺激动剂的体外反应。
J Clin Endocrinol Metab. 2013 Dec;98(12):E1880-90. doi: 10.1210/jc.2013-1987. Epub 2013 Sep 30.
6
Cabergoline for Cushing's disease: A case report.卡麦角林治疗库欣病：一例报告。
Endocrinol Nutr. 2015 Dec;62(10):516-8. doi: 10.1016/j.endonu.2015.07.002. Epub 2015 Aug 22.
7
Cortisol diurnal rhythm and quality of life after successful medical treatment of Cushing's disease.库欣病成功治疗后皮质醇昼夜节律与生活质量。
Pituitary. 2013 Dec;16(4):536-44. doi: 10.1007/s11102-012-0452-2.
8
Cushing's disease in dogs: cabergoline treatment.
Res Vet Sci. 2008 Aug;85(1):26-34. doi: 10.1016/j.rvsc.2007.08.009. Epub 2007 Oct 29.
9
A 12-month phase 3 study of pasireotide in Cushing's disease.一项为期 12 个月的培塞利肽治疗库欣病的 3 期研究。
N Engl J Med. 2012 Mar 8;366(10):914-24. doi: 10.1056/NEJMoa1105743.
10
Pituitary-targeted medical therapy of Cushing's disease.库欣病的垂体靶向药物治疗
Expert Opin Investig Drugs. 2008 May;17(5):669-77. doi: 10.1517/13543784.17.5.669.

引用本文的文献

1
Update on Medical Treatment of Cushing's Syndrome.库欣综合征的医学治疗进展
Drugs. 2025 Sep 15. doi: 10.1007/s40265-025-02223-8.
2
Management of Osilodrostat Therapy in Patients With Cushing's Syndrome: A Modified Delphi Consensus Panel.库欣综合征患者奥西卓司他治疗的管理：一个改良的德尔菲共识小组
J Endocr Soc. 2025 Jun 27;9(8):bvaf103. doi: 10.1210/jendso/bvaf103. eCollection 2025 Aug.
3
A Prospective Trial With Ketoconazole Induction Therapy and Octreotide Maintenance Treatment for Cushing's Disease.一项关于酮康唑诱导治疗和奥曲肽维持治疗库欣病的前瞻性试验。
J Endocr Soc. 2025 May 23;9(7):bvaf089. doi: 10.1210/jendso/bvaf089. eCollection 2025 Jul.
4
Medical management pathways for Cushing's disease in pituitary tumors centers of excellence (PTCOEs).垂体瘤卓越中心（PTCOEs）中库欣病的医学管理路径。
Pituitary. 2025 Jan 29;28(1):23. doi: 10.1007/s11102-024-01485-x.
5
Cushing syndrome.库欣综合征
Nat Rev Dis Primers. 2025 Jan 23;11(1):4. doi: 10.1038/s41572-024-00588-w.
6
Medical Treatment of Cushing's Syndrome.库欣综合征的医学治疗
Endocrinol Metab (Seoul). 2025 Feb;40(1):26-38. doi: 10.3803/EnM.2024.501. Epub 2025 Jan 13.
7
Advances in pharmacological treatment of Cushings disease.库欣病药物治疗的进展
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2024 Jul 28;49(7):1023-1033. doi: 10.11817/j.issn.1672-7347.2024.240306.
8
Current and Emerging Pharmacological Therapies for Cushing's Disease.库欣病的现有和新兴药物治疗方法。
Curr Pharm Des. 2024;30(10):757-777. doi: 10.2174/0113816128290025240216110928.
9
Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing's disease.单独使用或联合使用培高利特和卡麦角林治疗库欣病的长期疗效和安全性。
Front Endocrinol (Lausanne). 2023 Oct 9;14:1165681. doi: 10.3389/fendo.2023.1165681. eCollection 2023.
10
An individualized approach to the management of Cushing disease.个体化治疗库欣病的方法。
Nat Rev Endocrinol. 2023 Oct;19(10):581-599. doi: 10.1038/s41574-023-00868-7. Epub 2023 Aug 3.